Tag:
Meridia
Latest Headlines
Latest Headlines
Abbott pulls Meridia in multiple markets
At the request of the FDA, Abbott Laboratories is voluntarily withdrawing Meridia (sibutramine) from the U.S. market following concerns that the drug may increase risk of serious cardiovascular
FDA panel offers no final answer on Meridia
Once again, we have a split vote from an FDA advisory panel asked whether a drug is too risky to stay on the market. The FDA's handpicked experts voted eight to six to two on Abbott Laboratories'
FDA staff questions Meridia safety
As the advisory panel showdown over Abbott Labs' weight loss drug Meridia nears, FDA scientists have released their assessment of the safety data. Their conclusion? They are worried about the deaths
Abbott, NEJM disagree on Meridia data
A 180-degree difference in interpretation of new study data has Abbott Labs and the New England Journal of Medicine at odds over the diet pill Meridia. Abbott says data from the multi-year,
NEJM fuels calls to withdraw Abbott's Meridia
Get ready for more controversy over Abbott Laboratories' ( NYSE: ABT ) diet pill Meridia. Two weeks before an FDA advisory panel meets to consider the drug's safety, final data from a long-term,
FDA advisors to weigh Meridia's safety
Abbott Laboratories' ( NYSE: ABT ) weight-loss drug Meridia will get a day in court--FDA court, that is. An FDA advisory panel will review the drug Sept. 15, analyzing data on Meridia's safety risks.
Regulators probe diet drug safety after study
More diet pill news today, and it's not encouraging. European regulators say Abbott Laboratories' Meridia drug should be suspended because of associated risks of stroke and heart attack. The EMEA
Abbott drug safety in FDA spotlight
Abbott Laboratories gets a one-two safety punch today. First, the FDA issued a reminder warning about birth defects in babies born to pregnant women who take Depakote, the epilepsy drug that's also
U.S., Europe reviews safety of Abbott obesity med
FDA is sifting through some preliminary data suggesting that Abbott Laboratories' obesity drug Meridia (sibutramine) may carry cardiovascular risks. At this point the operative word is "preliminary;"
